WVE WAVE Life Sciences

Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference

Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 13, 2026 at 2:15 p.m. PT / 5:15 p.m. ET.

A live webcast of the presentation can be accessed by visiting “Investor Events” on the Investors section of the Wave Life Sciences website: . A replay of this presentation will be archived and available on the site for a limited time following the event.

About Wave Life Sciences

Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference, and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s diversified pipeline includes clinical programs in obesity, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington’s disease, as well as several preclinical programs utilizing the company’s broad RNA therapeutics toolkit. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit and follow Wave on and .

Contact:

Kate Rausch

VP, Corporate Affairs and Investor Relations





Investors:

James Salierno

Director, Investor Relations



Media:

Katie Sullivan

Senior Director, Corporate Communications





EN
05/01/2026

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on WAVE Life Sciences

Yun Zhong
  • Yun Zhong

Clinical Data From Fellow INHBE Program Provide Strong POC

ARO-ALK7 Shows Promising mRNA Knockdown and Fat Reduction. ALK7 is an Activin receptor that is encoded by the ACVR1C gene and expressed in adipose tissue. ARWR reported placebo-adjusted visceral fat reduction of 14.1% from a single dose of 200mg at week 8. According to ARWR, the ARO-ALK7 program is

 PRESS RELEASE

Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Co...

Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 13, 2026 at 2:15 p.m. PT / 5:15 p.m. ET. A live webcast of the presentation can be accessed by visiti...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch